Robert P.Good, MD
Former Chief of Orthopaedic Surgery at Bryn Mawr Hospital and Team Physician for Villanova Men’s Basketball.
A device company built around one unsolved problem.
Caeruleum Biotechnologies, INC. is a preclinical orthopedic medical device company. The LunaFlex Meniscus is designed to restore physiologic load distribution across the tibiofemoral joint, to mitigate progression to post-traumatic osteoarthritis, and to give the joint a durable mechanical solution measured in decades rather than years.
Origin
The design came first. The company followed.
The first concepts and sketches for LunaFlex were developed in early October 2015. The earliest work began with a straightforward question: if damaged or missing meniscal tissue could not be repaired, could a synthetic structure be designed to restore the meniscus’s load-distributing role rather than simply remove more tissue?
That question became a long-running design program. The original concept evolved through repeated work on the implant’s geometry, fiber-reinforced structure, fixation approach, and intended surgical workflow. The application that became U.S. Patent No. 11,147,677 was filed in January 2017 and granted on 19 October 2021.
Over the following decade – as the paths of Caeruleum’s founders converged and led to the company’s formation in 2022 – the design, material selection, and market and regulatory positioning were refined. Caeruleum was built to carry that early invention forward as the LunaFlex platform and prepare the program for public launch.
Intellectual property
The protected structure at the center of LunaFlex.
The intellectual property supporting Caeruleum’s LunaFlex program is anchored by U.S. Patent No. 11,147,677, “Artificial meniscus,” which describes a fiber-reinforced composite meniscus encased in a bioresorbable scaffold.
A further provisional patent application was filed in April 2026, extending the estate to the fixation system, surgical instruments, and AI- and machine-learning–enabled preoperative sizing and planning software.
The issued patent is a public document, and anyone evaluating the program can read its claims in full:
Why now
Three decades defined the device. The last three years defined the timing.
The design problem is old. What has changed recently is the ground it lands on.
Regulatory clarity
A 2023 FDA advisory panel set out what a meniscal implant of this class has to demonstrate. The path we would otherwise have had to define ourselves is now marked.
Materials maturity
The materials the design depends on carry established safety histories and are in production today – no novel-material risk, and no supply chain to invent.
Payer pressure
Published evidence on the efficacy of arthroscopic partial meniscectomy has moved payers toward joint-preserving alternatives. Demand is forming ahead of supply.
FDA Orthopaedic and Rehabilitation Devices Panel, 2023 · Sihvonen et al., FIDELITY, NEJM.
Clinical advisory board
Key Opinion Leaders
Our clinical advisors bring experience in orthopaedic surgery, sports medicine, quality and safety, and health economics to the development of the LunaFlex program.
Eric L.Hume, MD
Director of Orthopaedic Quality & Safety at Penn Medicine and Senior Fellow at the Leonard Davis Institute.
Matthew T.Kleiner, MD
Orthopaedic Sports Medicine Surgeon at Cooper University Hospital and Team Physician for Rowan University Athletics.
Mindy George-Weinstein, PhD
Chief Research & Science Officer and a Board Trustee at the Philadelphia College of Osteopathic Medicine.
Continue exploring
Follow the program from problem to platform.
Go deeper into the LunaFlex design or meet the people advancing it.